Immediate Impact
66 standout
Citing Papers
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Works of Iveta Kudaba being referenced
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
2019
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Iveta Kudaba | 605 | 468 | 94 | 22 | 710 | |
| Rita P. Dalal | 407 | 302 | 139 | 20 | 604 | |
| Pier Paolo Fattori | 271 | 250 | 73 | 23 | 631 | |
| Akiko Kawano Nagatsuma | 377 | 375 | 147 | 16 | 633 | |
| Nathalie Théou–Anton | 358 | 312 | 78 | 28 | 649 | |
| Fabiola Lorena Rojas Llimpe | 494 | 493 | 214 | 32 | 776 | |
| Salah-Eddin Al-Batran | 588 | 422 | 246 | 30 | 788 | |
| Maria Marples | 500 | 350 | 74 | 30 | 700 | |
| A.R. Abdul Razak | 429 | 279 | 59 | 26 | 737 | |
| Guanghai Dai | 348 | 344 | 179 | 33 | 650 | |
| Douglas Adkins | 353 | 383 | 61 | 18 | 638 |
All Works
Loading papers...